Articles tagged with Pancreatic Cancer
A novel pancreatic cancer vaccine, Algenpantucel-L, has shown promising results in a Phase 2 study, improving 12-month disease-free and overall survival rates. The vaccine is designed to trigger the patient's own immune system to destroy cancer cells.
Researchers at Mayo Clinic have developed a minimally invasive technique to detect pancreatic cancer in the nearby small intestine using a light probe. The study found that this technology can detect all 10 pancreatic cancers tested, with high accuracy rates and potential for early detection without invasive procedures.
A new biomarker, PEAK1, has been identified for pancreatic cancer, a disease with low survival rates. Inhibition of PEAK1-dependent signaling sensitizes PDAC cells to existing chemotherapies.
Researchers have discovered a new class of malaria transmission-blocking compounds that work by inhibiting bumped kinase I, blocking the parasite's infectious stage. Genetic variation is also linked to high blood pressure, with researchers finding that inhibiting renin pathway activity can return blood pressure to normal levels.
Researchers discovered that mutant Kras manipulates metabolic pathways to support tumor growth and progression in pancreatic cancer. The study found that turning off the oncogene caused tumors to regress and metabolic changes correlated with gene expression changes.
Researchers at Dana-Farber Cancer Institute discovered that advanced pancreatic cancers in mice cannot survive without the mutant Kras oncogene, which rewires key metabolic pathways. The study suggests that targeting these altered metabolic pathways might be a potential approach to treat the deadly cancer.
Researchers found that over 40% of high-risk individuals have detectable pancreatic lesions, which increase with age. Endoscopic ultrasound is more effective than MRI and CT scans in detecting these lesions. Early detection can help prevent the disease by removing precancerous lesions.
A first-of-its-kind clinical trial demonstrated the feasibility of selecting treatment based on individual molecular characteristics in advanced pancreatic cancer. The study found that biopsies could be safely conducted and multiple drug targets identified, suggesting potential benefits for some patients.
A Mayo Clinic study found that the dietary supplement gamma-linoleic acid can inhibit the growth of a subset of pancreatic cancer cells and selectively promote cancer cell death in mice. Combining GLA with chemotherapy drug gemcitabine significantly inhibited tumor growth.
A Mayo Clinic-led study has found that a combination of the novel drug TH-302 with standard drug gemcitabine delays cancer worsening in patients with advanced pancreatic cancer. The 2-drug combo showed a 5.6-month progression-free survival, significantly extending the average survival of six to seven months.
A new study published by the American College of Surgeons found that patients who underwent an operation as part of their cancer treatment and started a regular walking regimen experienced less fatigue than those who did not. After three months, the intervention group reported a 27% improvement in fatigue, compared to a 19% improvement...
A Johns Hopkins study of thousands of identical twins found that whole genome sequencing is not informative for predicting most common diseases. While the test can alert individuals to an increased risk of certain diseases, it fails to forewarn them of others they may ultimately develop.
Scientists at Fox Chase Cancer Center have discovered compounds that enhance the effects of gemcitabine, improving its ability to kill pancreatic cancer cells. This breakthrough could lead to a lower dose of chemotherapy with fewer side effects, potentially increasing survival rates for patients.
Researchers have developed a method to destroy cancer cells using the death cap mushroom's α-amanitin toxin without harming healthy cells. The toxin is linked to an antibody that targets a protein on cancer cells, inhibiting tumor growth and causing regression in mice.
Researchers at Fox Chase Cancer Center found that survivin levels were associated with longer disease-free survival and better response to chemotherapy in patients with pancreatic cancer. The study suggests that survivin could be a useful tool for identifying patients who may benefit from specific treatments.
Researchers found success with irreversible electroporation to treat primary and metastatic liver cancer; the technique is now being implemented as a treatment for pancreatic cancer. Two out of eight participants had successful resections after IRE, with improved survival rates compared to traditional treatments.
Researchers have identified a new protein, S100PBP, that suppresses cathepsin Z and reduces pancreatic cancer cells' ability to attach to other tissues. This discovery may lead to the development of novel preventive and therapeutic targets for pancreatic cancer.
Scientists at Fred Hutchinson Cancer Research Center and TGen have discovered a way to break down the biological barrier surrounding pancreatic cancer tumors, allowing chemotherapy drugs to reach the cancerous tissue. This breakthrough could lead to improved survival rates for patients with pancreatic cancer.
Researchers at Fred Hutchinson Cancer Center have discovered a way to break down the biological barrier surrounding pancreas cancer tumors, allowing chemotherapy to penetrate and increase survival rates. The new approach shows significant promise for treating this deadly disease.
The Pancreatic Cancer Action Network and AACR have awarded $1.2 million in grants to two postdoctoral fellows, Stephanie K. Dougan and Oliver G. McDonald, to advance pancreatic cancer research through immunotherapy and epigenetic reprogramming studies.
A phase I clinical trial of patients with advanced pancreatic cancer showed promise with rigosertib, achieving stable disease in 11 of 19 patients for a median duration of 113 days. The drug targets PLK1 and PI3K signals that allow cancer cells to divide rapidly.
Researchers have found that combining gemcitabine with nab-paclitaxel increases intratumoral gemcitabine levels by reducing the primary metabolizing enzyme, cytidine deaminase. This combination may lead to improved patient outcomes and better administration of therapeutic treatments.
Breast cancer death rates are declining across the EU, with a predicted drop of 9% for women and 13% among young women. Pancreatic cancer deaths are rising, but overall cancer mortality rates are falling due to advancements in treatment and prevention.
The 9th annual Seena Magowitz Celebrity Golf Classic raised funds for pancreatic cancer research at the Translational Genomics Research Institute (TGen). The event supported new international clinical trials and initiatives against pancreatic cancer.
A mutant protein in nearly all pancreatic cancers plays a role in its development and continued growth, according to a U-M study. Inactivating Kras eliminated tumors in mice, but left fibrous areas similar to scar tissue, suggesting possible treatment targets.
Researchers at the Translational Genomics Research Institute and University of Arizona have received a grant to study targeted cancer therapies for pancreatic cancer, which shows promise in reducing side effects. The center aims to develop novel antitumor agents that can extend the productive lives of patients with cancer.
Researchers identified a molecular loop between mutated Kras, NF-κB, and IL-1α, which perpetuates inflammation, tumor growth, and poor survival in pancreatic cancer. This discovery suggests targeting IL-1α as a potential treatment avenue to block the elusive target of mutated Kras.
Researchers at the University of Pennsylvania School of Medicine have discovered that pancreatic cancer cells in an animal model begin to spread before clinically obvious tumor tissue is detected. Inflammation plays a crucial role in enhancing cancer progression, leading to the entry of cancer cells into the bloodstream. The study used...
Researchers have made significant progress in detecting and treating gastrointestinal cancers with new biomarkers, test, and treatments. Studies show promising results for detecting early stage pancreatic cancer and improving survival in patients with metastatic colorectal cancer.
A team of researchers identified genetic mutations in OATP1B1 and OATP1B3 as the cause of Rotor syndrome, a rare genetic disorder characterized by jaundice. Complete deficiency of these proteins causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.
A Stanford study found that a well-known protein complex controls DNA expression and prevents pancreatic cancer. The researchers discovered genetic changes in the protein complex were present in nearly a third of human pancreatic cancers, suggesting its role in tumor suppression.
Researchers at Cardiff University have secured a £2M MRC Programme Grant to investigate the potential of a calcium-like molecule in protecting against enzymes that trigger pancreatitis. The team aims to better understand stellate cells, which may be the link between chronic pancreatitis and pancreatic cancer.
Researchers have identified mutations in the ATM gene as a potential risk factor for increased pancreatic cancer risk. Studies found that ATM gene mutations were present in four of 166 patients with pancreatic cancer, but absent in healthy spousal controls.
Scientists at Thomas Jefferson University's Center for Translational Medicine have found that reducing N-cadherin levels in pancreatic cancer cells can slow down their mobility and prolong survival in mice by 25 percent. This discovery could lead to new targeted therapies for pancreatic cancer.
Research found that patients with high levels of nickel and selenium had a lower risk of pancreatic cancer, whereas those with high levels of lead, arsenic, and cadmium had an increased risk. These findings suggest a potential role of trace elements in pancreatic carcinogenesis.
Researchers at IRB Barcelona have discovered a new genetic program that converts epithelial cells into mobile invasive cells, which is common in embryonic development and tumour progression. The GATA6 gene plays a key role in this process, triggering survival factors and degrading the cellular matrix to facilitate cell migration.
The RTOG is launching a phase I trial testing ganitumab for locally advanced pancreatic cancer. The trial will investigate the safety and efficacy of ganitumab when combined with chemoradiation treatment. By targeting the IGF-1R pathway, ganitumab may offer a new approach to treating this aggressive form of cancer.
Researchers developed two new QCancer algorithms to predict patients most likely to have pancreatic and bowel cancer, improving early diagnosis and treatment options. The calculators were successful in predicting 62% of pancreatic cancers and 70% of bowel cancers diagnosed over the following two years.
Scientists developed a vaccine that reduces tumors by 80% in mouse models of breast and pancreatic cancer. The vaccine uses a unique carbohydrate signature to train the immune system to target cancer cells.
The 'Seena I' clinical trial aims to find a cure for pancreatic cancer by attacking all components of the tumor. The trials are supervised by the Pancreatic Cancer Research Team and involve four clinical sites across the nation.
Researchers have discovered that connexin 36 protects mouse pancreatic beta-cells against immune molecules prevalent in type 1 diabetes. Additionally, a study found that PTHrP drives breast tumor initiation, progression, and metastasis in mice, suggesting it as a potential therapy target.
A study published in Gut found that specific types of mouth bacteria are associated with pancreatic cancer. The researchers identified two key species - Neisseria elongata and Streptococcus mitis - which were significantly less present in cancer patients' mouths, while Granulicatella adjacens levels were higher.
A new drug combination of gemcitabine and nab-paclitaxel has shown impressive results in a clinical trial for patients with advanced pancreatic cancer. The study, led by Dr. Daniel Von Hoff, found that about half the patients showed reductions in tumor size and about 50 percent lived at least a year.
The study reveals that EGFR plays a crucial role in the development of KRAS-driven pancreatic cancer, blocking its progression without it. Researchers found that mice with EGF receptor deletion had blocked pancreatic cancer development.
Masaaki Tamura's team creates a targeted therapy to combat lung cancer by delivering a receptor gene to cancer cells via nanoparticles, stimulating the immune system to prevent tumor growth. The therapy uses a cationic peptide to guide the gene to cancerous cells, offering a non-invasive treatment option for lung cancer patients.
Mattress Firm Foundation is committed to raising awareness and funding for TGen's globalCure clinical trials, focusing on funding research and clinical trials. The company has already raised over $400,000 through employee donation programs and online fundraising platforms.
A prospective cohort study found that a tumor marker and targeted endoscopic ultrasound can detect stage 1 pancreatic cancer in high-risk populations more effectively than standard means of detection. The study identified a total of one patient with stage 1 disease among 546 enrolled participants.
Scientists developed a gene-based test to identify precancerous pancreatic cysts, which can help patients avoid unnecessary surgeries. The test found mutations in KRAS and GNAS genes, associated with pancreatic cancer, but not in benign cysts.
Researchers at Johns Hopkins have identified two genes, ATRX and DAXX, that contribute to the lengthening of telomeres in cancer cells. The study found a correlation between mutations in these genes and alternative lengthening of telomeres in various types of tumors.
Researchers at Mayo Clinic have found a reliable method to detect pancreatic cancer through DNA testing of stool samples, with a marker detecting methylated genes in 70% of patients. This noninvasive test may lead to increased early detection and improved survival rates for those diagnosed with the disease.
Researchers have successfully used oncolytic viruses to infect and kill pancreatic cancer stem cells, which are thought to cause disease recurrence and metastasis. This breakthrough could provide a potential therapy for pancreatic cancer patients, particularly those with tumors resistant to conventional chemotherapy and radiation.
Researchers have identified a protein in blood serum that distinguishes pancreatic cancer from non-cancerous conditions. The discovery suggests a potential blood test to detect pancreatic cancer at an earlier stage.
A group of Ohio greenhouse growers partners with the Translational Genomics Research Institute to sell 'denim shock wave petunias' in support of pancreatic cancer awareness. The program aims to raise funds for TGen's globalCure initiative, which seeks to find a cure for pancreatic cancer.
Researchers at UCSF have discovered a link between inflammation and the early formation of pancreatic cancer. They found that two molecular signals produced in the pancreas during inflammation can help initiate the early stages of cancer, while another protein may be a clinical indicator of cancer stage.
Mattress Firm has named Translational Genomics Research Institute as its charitable partner of choice to support globalCure's fight against pancreatic cancer. The company will donate $50 to globalCure for every Simmons Beautyrest dual floor sample sold nationwide, aiming to raise over $100,000.
NYU School of Medicine researcher Cosimo Commisso will receive a grant to investigate the role of fluid uptake in pancreatic cancer cells. The goal is to understand how this process contributes to tumor development and identify potential targeting strategies.
A large case-control study found that taking aspirin at least once a month can reduce the risk of pancreatic cancer by 26% compared to non-users. The effect was also seen in those taking low-dose aspirin for heart disease prevention, with a 35% lower risk.
The Pancreatic Cancer Action Network and the American Association for Cancer Research awarded 10 grants totaling nearly $3 million to support innovative pancreatic cancer research. The recipients will be honored at the AACR Annual Meeting, with a focus on building a comprehensive and coordinated pancreatic cancer research community.
The Pancreatic Cancer Action Network and AACR have awarded Jennifer M. Bailey and E. Scott Seeley $600,000 grants to pursue groundbreaking research on pancreatic cancer initiation and progression. Their projects focus on novel insights into KRAS mutations and transport proteins as modifiers of oncogenic signaling.
Researchers at the University of Pennsylvania have discovered a novel way to treat pancreatic cancer by activating the immune system to destroy the cancer's scaffolding. The strategy was tested in a small cohort of patients with advanced pancreatic cancer, resulting in substantial tumor shrinkage and reduced metabolic activity.